Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2176 to 2190 of 9092 results

  1. Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

    Awaiting development Reference number: GID-TA10773 Expected publication date: TBC

  2. Ondansetron for treating alcohol-use disorder [ID6341]

    Awaiting development Reference number: GID-TA11375 Expected publication date: TBC

  3. Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]

    In development Reference number: GID-TA11410 Expected publication date: TBC

  4. Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]

    Awaiting development Reference number: GID-TA11575 Expected publication date: TBC

  5. Sibeprenlimab for treating IgA nephropathy [ID6604]

    Awaiting development Reference number: GID-TA11668 Expected publication date: TBC

  6. Atrasentan for treating primary IgA nephropathy [ID6558]

    Awaiting development Reference number: GID-TA11756 Expected publication date: TBC

  7. Ravulizumab for treating primary IgA nephropathy [ID6703]

    Awaiting development Reference number: GID-TA11919 Expected publication date: TBC

  8. CM-AT for behaviours associated with autism in children and young people [ID6731]

    Awaiting development Reference number: GID-TA11955 Expected publication date: TBC

  9. Obinutuzumab for treating primary membranous nephropathy [ID6751]

    Awaiting development Reference number: GID-TA11983 Expected publication date: TBC

  10. School-based interventions: physical and mental health and wellbeing promotion

    In development Reference number: GID-QS10070 Expected publication date: TBC

  11. Infant, children and young people's experience of health care

    Awaiting development Reference number: GID-QS10102 Expected publication date: TBC

  12. Managing symptoms with an uncertain cause

    Awaiting development Reference number: GID-QS10103 Expected publication date: TBC

  13. Readmission to ICU within 48hrs

    Awaiting development Reference number: GID-QS10105 Expected publication date: TBC

  14. Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

    Awaiting development Reference number: GID-QS10106 Expected publication date: TBC

  15. Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]

    Awaiting development Reference number: GID-TA11876 Expected publication date: TBC